Welcome to our dedicated page for Tactile Systems SEC filings (Ticker: TCMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tactile Systems Technology, Inc. (Tactile Medical) SEC filings page for ticker TCMD provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical technology company incorporated in Delaware, Tactile Medical files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K under Commission File Number 001-37799.
Through these filings, investors can review detailed information on Tactile Medical’s business, including its focus on at-home therapies for lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. Periodic reports describe revenue from sales and rentals of the lymphedema product line and sales of the airway clearance product line, along with discussions of gross margin, operating expenses, net income or loss and non-GAAP measures such as Adjusted EBITDA as defined by the company.
Current reports on Form 8-K document material events, such as the release of quarterly financial results and the authorization of share repurchase programs for the company’s common stock. These filings may include information on the size and duration of repurchase authorizations and the company’s intention to fund them from cash and future cash flows.
On Stock Titan, TCMD filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight key points from lengthy documents, helping users quickly understand topics such as segment performance, capital allocation decisions and risk factor discussions without reading every page. Users can also review insider-related filings, including Forms 3, 4 and 5, to track equity transactions by directors and officers, and proxy statements on Schedule 14A for information on governance and executive compensation.
Whether you are analyzing Tactile Medical’s financial history, monitoring new 8-K disclosures or looking for details on its at-home therapy business, this page centralizes the company’s official SEC filings with concise AI-generated insights.
Morgan Stanley and Morgan Stanley Capital Services LLC have disclosed significant passive stakes in Tactile Systems Technology Inc. common stock. As of 12/31/2025, Morgan Stanley reports beneficial ownership of 1,293,289 shares, representing 5.8% of the class, with all voting and dispositive power shared.
Morgan Stanley Capital Services LLC reports beneficial ownership of 1,154,700 shares, or 5.2% of the class, also with shared voting and dispositive power. The firms certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Tactile Systems Technology.
Dimensional Fund Advisors LP has filed an amended Schedule 13G reporting beneficial ownership of Tactile Systems Technology Inc common stock. Dimensional is reported as having beneficial ownership of 1,095,235 shares, representing 4.9% of the outstanding common stock as of the event date of 12/31/2025. It has sole voting power over 1,069,882 shares and sole dispositive power over 1,095,235 shares.
The shares are owned by various funds and accounts that Dimensional advises or manages, and Dimensional disclaims beneficial ownership beyond what is required for Section 13(d) reporting. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tactile Systems Technology Inc.
Tactile Systems Technology’s Senior Vice President of Marketing & Clinical Affairs, Kristie Burns, reported a planned sale of company stock. On January 2, 2026, she sold 5,139 shares of common stock at a price of $28.85 per share under transaction code “S,” which indicates a sale. After this trade, she beneficially owned 72,401 shares of Tactile Systems Technology common stock in direct ownership.
The sale was made pursuant to a Rule 10b5-1(c) trading plan, which the disclosure notes was adopted on September 11, 2025. Such plans allow insiders to prearrange trades of company stock according to preset instructions, helping separate personal trading decisions from access to inside information.
Tactile Systems Technology, Inc. (TCMD) announced a new share repurchase program authorizing the company to buy back up to
The company stated it currently expects to fund the program with existing cash and future cash flows. TCMD also furnished a press release disclosing results of operations and financial condition for its most recently completed fiscal quarter as Exhibit 99.1, which, under applicable rules, is not deemed filed.
On 08/08/2025 Sheri Louise Dodd, a director and the Chief Executive Officer of Tactile Systems Technology, sold 7,762 shares of the company’s common stock at $12.356 per share. The Form 4 states the shares were sold to cover taxes associated with the settlement of restricted stock units.
Following the reported sale, Ms. Dodd beneficially owns 173,479 shares, held directly. The disclosure is a routine RSU tax-withholding sale and the form does not report any additional purchases, option exercises, or other material changes to her ownership.
Tactile Systems Technology, Inc. (TCMD) submitted a Form 144 reporting a proposed sale of 7,762 common shares with an aggregate market value of $95,905.72. The filing names Fidelity Brokerage Services LLC as the broker and lists 22,292,145 shares outstanding. The approximate sale date is 08/08/2025 and the securities are listed on NASDAQ. The reported acquisition occurred on 08/07/2025 and is described as Restricted Stock Vesting, with payment characterized as Compensation. The form indicates Nothing to Report for securities sold in the past three months and was submitted as a LIVE filing. The signature section includes the required representation about lack of undisclosed material information.
Cadian Capital Management, LP, its general partner Cadian Capital Management GP, LLC, and managing member Eric Bannasch filed Amendment No. 2 to Schedule 13G on Tactile Systems Technology, Inc. (NASDAQ: TCMD).
- Current position: 2,192,823 common shares as of 7 Aug 2025, representing 9.8 % of outstanding stock (22,292,145 shares outstanding).
- Prior position: 2,309,616 shares (10.4 %) as of 30 Jun 2025. The filing therefore discloses a net reduction of 116,793 shares and a drop below the 10 % reporting threshold.
- All shares are held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP. The adviser exercises shared voting and dispositive power; no sole power is reported.
- The securities are held in the ordinary course; the group affirms no intent to influence control of the issuer.
The amendment signals that a major institutional holder remains the company’s largest known shareholder but has modestly trimmed its passive stake.